Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Energy Fuels Aktie: Achtung, Aufholpotenzial! (Aktiencheck) +++ ENERGY FUELS Aktie -3,11%

PRECIGEN Aktie

 >PRECIGEN Aktienkurs 
1.352 EUR    -1.7%    (Tradegate)
Ask: 1.391 EUR / 2156 Stück
Bid: 1.332 EUR / 2253 Stück
Tagesumsatz: 1111 Stück
Realtime Kurs von 8 bis 22 Uhr!
PRECIGEN Aktie über LYNX handeln
>PRECIGEN Performance
1 Woche: +7,7%
1 Monat: +10,3%
3 Monate: +14,1%
6 Monate: +17,2%
1 Jahr: +0,8%
laufendes Jahr: +65,0%
>PRECIGEN Aktie
Name:  PRECIGEN INC.
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US74017N1054 / A2PZG1
Symbol/ Ticker:  I5X (Frankfurt) / PGEN (NASDAQ)
Kürzel:  FRA:I5X, ETR:I5X, I5X:GR, NASDAQ:PGEN
Index:  -
Webseite:  https://precigen.com/
Marktkapitalisierung:  386.82 Mio. EUR
Umsatz:  3.64 Mio. EUR
EBITDA:  -77.34 Mio. EUR
Gewinn je Aktie:  -0.407 EUR
Schulden:  4.69 Mio. EUR
Liquide Mittel:  69.47 Mio. EUR
Umsatz-/ Gewinnwachstum:  25.9% / -
KGV/ KGV lG:  - / -
KUV/ KBV/ PEG:  97.95 / 7 / -
Gewinnm./ Eigenkapitalr.:  - / -278.55%
Dividende je Aktie:  -
Dividendenrendite/ -schätzung:  - / -
Insiderhandel:  -
Suchwörter:  PRECIGEN
Letzte Datenerhebung:  05.07.25
>PRECIGEN Eigentümer
Aktien: 295.18 Mio. St.
f.h. Aktien: 147.8 Mio. St.
Insider Eigner: 10.52%
Instit. Eigner: 67.05%
>PRECIGEN Peer Group

 
14.05.25 - 22:09
 Precigen Reports First Quarter 2025 Financial Results and Business Updates (PR Newswire)
 
PRGN-2012 has the potential to be the first- and best-in-class treatment for RRP Company's BLA for PRGN-2012 for the treatment of adults with RRP is under priority review by the FDA with a PDUFA target action date set for August 27, 2025 RRP is a rare, debilitating chronic disease with......
16.04.25 - 14:06
 Precigen and Recurrent Respiratory Papillomatosis Foundation to Host the 2025 International RRP Awareness Day on June 11th (PR Newswire)
 
– International event will raise awareness and bring together RRP patients, caregivers, and the healthcare community supporting them – – Recurrent respiratory papillomatosis is a rare, debilitating, chronic disease that impacts both children and adults and is mainly driven by HPV 6/11......
20.03.25 - 00:45
 Precigen, Inc. (PGEN) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
 
Precigen (PGEN) delivered earnings and revenue surprises of 33.33% and 2.86%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?...
19.03.25 - 21:06
 Precigen Reports Full Year 2024 Financial Results and Business Updates (PR Newswire)
 
FDA granted priority review to Company's BLA for PRGN-2012 for the treatment of adults with recurrent respiratory papillomatosis and set PDUFA target action date for August 27, 2025 Results from pivotal clinical study of PRGN-2012 were published in The Lancet Respiratory Medicine......
18.03.25 - 22:39
 Precigen FY 2024 Earnings Preview (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
13.03.25 - 13:06
 Precigen to Announce Full Year 2024 Financial Results and Provide Business Updates on March 19th (PR Newswire)
 
GERMANTOWN, Md., March 13, 2025 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the Company will release full year 2024 financial results and......
25.02.25 - 16:09
 Precigen gets FDA Priority Review for its respiratory tract tumor treatment (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
25.02.25 - 14:06
 FDA Grants Priority Review to Precigen′s BLA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis with PDUFA Target Action Date Set for August 27, 2025 (PR Newswire)
 
– Priority review reduces the BLA review timeline to 6-months and is granted to therapies that, if approved, would provide significant improvements in the treatment, diagnosis or prevention of serious conditions – – If approved, PRGN-2012 would be the first and only available FDA-approved......
13.01.25 - 13:06
 Precigen to Present Plans for Realizing Commercial Vision for PRGN-2012 at the 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
 
– PRGN-2012 has potential to be first FDA-approved therapeutic for treatment of RRP, a rare and devastating chronic disease – – Company completed BLA submission for PRGN-2012 for treatment of adults with RRP – – Commercial readiness activities underway in anticipation of potential launch......
09.01.25 - 14:31
 Precigen to Present at the 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
 
GERMANTOWN, Md., Jan. 9, 2025 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced Helen Sabzevari, PhD, President and CEO of Precigen, will......
02.01.25 - 21:15
 PGEN Stock Surges More Than 40% in a Week: What′s Driving the Rally? (Zacks)
 
The upside in Precigen's stock comes after it completes the rolling submission of an FDA filing for its first potentially marketed product....
31.12.24 - 14:09
 Precigen Soars: Biologics License Application Submission For PRGN-2012 Targets First FDA-Approved Recurrent Respiratory Papillomatosis Treatment (Benzinga)
 
Precigen submits BLA for PRGN-2012 gene therapy targeting RRP, a rare and life-threatening condition with no cure. read more...
30.12.24 - 13:03
 Precigen Completes Submission of BLA with Request for Priority Review to the FDA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis (PR Newswire)
 
– PRGN-2012 has the potential to be the first FDA-approved therapeutic for the treatment of adults with RRP, a rare and devastating chronic disease for which the current standard-of-care is repeated surgeries – – PRGN-2012 received Breakthrough Therapy Designation from the FDA and Orphan......
27.12.24 - 15:18
 Precigen announces $79 million private placement offering of convertible preferred stock (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
27.12.24 - 15:03
 Precigen Announces $79.0 Million Private Placement Offering of Convertible Preferred Stock (PR Newswire)
 
GERMANTOWN, Md., Dec. 27, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that it has entered into a securities purchase agreement for......
15.11.24 - 00:48
 Precigen, Inc. (PGEN) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
 
Precigen (PGEN) delivered earnings and revenue surprises of -12.50% and 13.36%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?...
14.11.24 - 22:54
 Precigen GAAP EPS of -$0.09 misses by $0.01, revenue of $0.95M misses by $0.33M (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
14.11.24 - 22:32
 Precigen Reports Third Quarter 2024 Financial Results and Business Updates (PR Newswire)
 
– Completed pre-BLA meeting with FDA with full alignment on content of BLA, including CMC module, and path for fourth quarter 2024 rolling BLA submission for PRGN-2012† in RRP under accelerated approval pathway – – Commercial and manufacturing readiness campaign underway for PRGN-2012 in......
15.08.24 - 07:03
 Precigen Inc reports results for the quarter ended in June - Earnings Summary (Reuters EN)
 
Precigen Inc reports results for the quarter ended in June - Earnings Summary...
15.08.24 - 00:48
 Precigen, Inc. (PGEN) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
 
Precigen (PGEN) delivered earnings and revenue surprises of -11.11% and 43.98%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Kein Kaiser kann, was unser ist, verschenken. - Friedrich Johann Christoph Schiller
Partner:    >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!